Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures and neuropsychiatric disorders for both hospital and home settings.
*Delayed quote courtesy of Google Finance.
View Stock Information
Lookup Date :
- Mar 11, 2019 Marinus Pharmaceuticals Provides Business Update and 2018 Financial Results
- Mar 06, 2019 Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related Epilepsy